Literature DB >> 23035063

Severe relapses under fingolimod treatment prescribed after natalizumab.

Diego Centonze1, Silvia Rossi, Francesca Rinaldi, Paolo Gallo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23035063     DOI： 10.1212/WNL.0b013e3182735c7a

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  20 in total

1.  Switching therapies in multiple sclerosis.

Authors:  Patricia K Coyle
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 2.  Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Authors:  Jiwon Oh; Paul W O'Connor
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

3.  Fingolimod after natalizumab and the risk of short-term relapse.

Authors:  Vilija G Jokubaitis; Vivien Li; Tomas Kalincik; Guillermo Izquierdo; Suzanne Hodgkinson; Raed Alroughani; Jeannette Lechner-Scott; Alessandra Lugaresi; Pierre Duquette; Marc Girard; Michael Barnett; Francois Grand'Maison; Maria Trojano; Mark Slee; Giorgio Giuliani; Cameron Shaw; Cavit Boz; Daniele L A Spitaleri; Freek Verheul; Jodi Haartsen; Danny Liew; Helmut Butzkueven
Journal:  Neurology       Date:  2014-03-07       Impact factor: 9.910

4.  Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.

Authors:  Michael Kaufman; Bruce A C Cree; Jerome De Sèze; Robert J Fox; Ralf Gold; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Xavier Montalbán; Bianca Weinstock-Guttman; Barry Ticho; Petra Duda; Amy Pace; Denise Campagnolo
Journal:  J Neurol       Date:  2014-11-09       Impact factor: 4.849

5.  Initiating oral fingolimod treatment in patients with multiple sclerosis.

Authors:  Barry A Singer
Journal:  Ther Adv Neurol Disord       Date:  2013-07       Impact factor: 6.570

Review 6.  Targeting cells in motion: migrating toward improved therapies.

Authors:  Jason W Griffith; Andrew D Luster
Journal:  Eur J Immunol       Date:  2013-05-13       Impact factor: 5.532

7.  Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors:  Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal:  J Neurol       Date:  2016-05-18       Impact factor: 4.849

Review 8.  Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Authors:  Joachim Havla; Ingo Kleiter; Tania Kümpfel
Journal:  Ther Clin Risk Manag       Date:  2013-10-03       Impact factor: 2.423

9.  Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Giancarlo Comi; Xavier Montalban; Helmut Butzkueven; Heinz Wiendl; Gavin Giovannoni; Hans-Peter Hartung; Tobias Derfuss; Yvonne Naegelin; Till Sprenger; Nicole Mueller-Lenke; Sarah Griffiths; Philipp von Rosenstiel; Rebecca Gottschalk; Ying Zhang; Frank Dahlke; Davorka Tomic
Journal:  Neurology       Date:  2015-05-29       Impact factor: 9.910

Review 10.  Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Authors:  Jong-Mi Lee; May H Han
Journal:  Patient Prefer Adherence       Date:  2015-05-21       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.